BTIG Research Reiterates “Buy” Rating for Maze Therapeutics (NASDAQ:MAZE)

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a report released on Wednesday,Benzinga reports. They currently have a $46.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 68.44% from the company’s current price.

A number of other equities research analysts have also issued reports on MAZE. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Truist Financial lowered their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Price Performance

MAZE stock opened at $27.31 on Wednesday. Maze Therapeutics has a one year low of $12.81 and a one year high of $53.65. The company’s fifty day moving average price is $27.63 and its 200-day moving average price is $33.32. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The company has a market capitalization of $1.51 billion, a PE ratio of -10.79 and a beta of 2.21.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, equities analysts anticipate that Maze Therapeutics will post -2.73 EPS for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the transaction, the chief executive officer directly owned 23,337 shares in the company, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00. Following the completion of the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at approximately $393,300. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 141,470 shares of company stock worth $3,902,714. 5.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MAZE. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth about $133,502,907,000. BlackRock Inc. acquired a new position in Maze Therapeutics in the second quarter valued at approximately $104,525,000. Janus Henderson Group PLC boosted its position in Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. boosted its position in Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after purchasing an additional 362,060 shares in the last quarter. Finally, Alphabet Inc. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $41,435,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.